Alder BioPharma (ALDR) Misses Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. SPY
9. FIX
10. IVBIY

Go back to Alder BioPharma (ALDR) Misses Q2 EPS by 4c

Alder Biopharm (ALDR) Bullish View Reiterated at Brean Following Q2 Result and Recent Positive ALD403 Data

July 27, 2016 10:36 AM EDT

Brean Capital analyst Jonathan Aschoff reiterated a Buy rating and $45 price target on Alder Biopharm (NASDAQ: ALDR) following Q2 results, recent data showing ALD403's durability and Phase 3 data in the 1st-half of 2017.

Aschoff commented, "Alder ended 2Q16 with cash of $450M, which should be able to support operations into 2H18. On Monday, Alder announced positive top-line 24-week data demonstrating sustained migraine... More

Alder Biopharm (ALDR) PT Bumped to $62 at Jefferies as 403 Continues To Advance

July 27, 2016 8:29 AM EDT

Jefferies analyst Brian Abrahams reiterated a Buy rating and bumped his price target on Alder Biopharm (NASDAQ: ALDR) to $62.00 (from $61.00) as '403 continues to advance.

Abrahams commented, "ALD403 continues to advance on track, and expenses were in line with expectations. Announced... More